CoverageForm 410-K10-Q8-K13D13G13F

CHE · Chemed Corp - Financials

Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.

Price · CHE

Income Statement

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Revenue$657.51M-$624.90M$618.80M$646.94M-$606.18M$595.88M$589.23M-
Cost of Revenue$441.75M-$427.99M$434.11M$430.53M-$396.19M$389.75M$385.13M-
Gross Profit$215.76M-$196.91M$184.69M$216.41M-$209.99M$206.13M$204.11M-
R&D----------
SG&A$114.32M-$105.78M$100.32M$105.59M-$101.98M$102.25M$115.87M-
Total Operating Expenses$572.93M-$514.02M$507.75M$516.90M-$514.02M$507.75M$516.90M-
D&A$16.87M-$13.66M$13.69M$16.02M-$13.15M$13.17M$15.81M-
Operating Income$84.58M-$74.75M$68.08M$94.76M-$92.16M$88.13M$72.33M-
Interest Expense$512.0K-$457.0K$443.0K$329.0K-$427.0K$429.0K$425.0K-
Income Tax$22.54M-$19.31M$18.62M$23.92M-$25.25M$22.94M$19.47M-
Net Income$66.30M-$64.24M$52.49M$71.76M-$75.78M$70.89M$65.02M-
EPS - Basic$4.85-$4.46$3.60$4.91-$5.04$4.70$4.30-
EPS - Diluted$4.84-$4.46$3.57$4.86-$5.00$4.65$4.24-

Balance Sheet

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Cash & Equivalents$16.86M$74.52M$129.75M$249.90M$173.88M$178.35M$238.45M$222.90M$313.35M$263.96M
Accounts Receivable$215.48M$182.57M$215.57M$184.88M$285.87M$171.16M$196.48M$184.96M$177.33M$181.51M
Inventory$7.21M$7.54M$8.24M$9.15M$7.79M$8.19M$9.90M$10.73M$10.71M$12.00M
Accounts Payable$65.70M$64.46M$48.09M$50.86M$47.69M$44.15M$44.94M$43.00M$56.20M$64.03M
Current Assets$274.06M$302.62M$395.24M$491.38M$502.38M$394.75M$490.44M$464.61M$539.62M$500.84M
Total Assets$1.54B$1.54B$1.62B$1.72B$1.73B$1.67B$1.77B$1.73B$1.73B$1.67B
Current Liabilities$321.42M$287.13M$292.04M$263.89M$290.56M$285.69M$264.78M$261.75M$281.97M$312.05M
Long-term Debt$91.20M---------
Total Liabilities$687.82M$558.78M$546.94M$519.36M$544.75M$549.58M$533.68M$527.69M$544.14M$560.22M
Stockholders' Equity$847.99M$979.40M$1.08B$1.20B$1.18B$1.12B$1.24B$1.21B$1.18B$1.11B
Retained Earnings$3.01B$2.96B$2.89B$2.83B$2.79B$2.72B$2.64B$2.57B$2.51B$2.45B

Cash Flow

Line itemQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Operating Cash Flow$88.22M---$32.74M---$84.55M-
Investing Cash Flow($37.79M)---($13.67M)---($19.39M)-
Financing Cash Flow($108.09M)---($23.54M)---($15.77M)-
CapEx$17.12M-$18.65M$15.81M$13.28M---$12.16M-
Free Cash Flow$71.10M---$19.46M---$72.39M-

Ratios

MetricQ1 '26Q4 '25Q3 '25Q2 '25Q1 '25Q4 '24Q3 '24Q2 '24Q1 '24Q4 '23
Profitability
Gross margin32.8%-31.5%29.8%33.5%-34.6%34.6%34.6%-
Operating margin12.9%-12.0%11.0%14.6%-15.2%14.8%12.3%-
EBITDA margin15.4%-14.1%13.2%17.1%-17.4%17.0%15.0%-
Net margin10.1%-10.3%8.5%11.1%-12.5%11.9%11.0%-
Free cash flow margin10.8%---3.0%---12.3%-
FCF / Net income1.07---0.27---1.11-
R&D / Revenue----------
SG&A / Revenue17.4%-16.9%16.2%16.3%-16.8%17.2%19.7%-
Effective tax rate25.4%-23.1%26.2%25.0%-25.0%24.5%23.0%-
Return on assets4.3%-4.0%3.1%4.2%-4.3%4.1%3.8%-
Return on equity7.8%-6.0%4.4%6.1%-6.1%5.9%5.5%-
Return on invested capital6.7%---------
Liquidity
Current ratio0.851.051.351.861.731.381.851.781.911.61
Quick ratio0.831.031.331.831.701.351.811.731.881.57
Cash ratio0.050.260.440.950.600.620.900.851.110.85
Leverage
Debt / Equity0.11---------
Debt / Assets0.06---------
Debt / EBITDA0.90---------
Interest coverage165.2x-163.6x153.7x288.0x-215.8x205.4x170.2x-
Equity multiplier1.811.571.511.431.461.491.431.441.461.51
Liabilities / Assets0.450.360.340.300.320.330.300.300.310.34
Efficiency
Asset turnover0.43-0.380.360.37-0.340.340.34-
Inventory turnover61.29-51.9547.4555.27-40.0236.3135.95-
Days sales outstanding120d-126d109d161d-118d113d110d-
Days inventory outstanding6d-7d8d7d-9d10d10d-
Days payable outstanding54d-41d43d40d-41d40d53d-
Cash conversion cycle71d-92d74d127d-86d83d67d-
Valuation
P / E78.0x-100.4x136.4x126.6x-120.2x116.7x151.4x-
P / B6.1x-6.0x6.0x7.7x-7.4x6.9x8.3x-
P / S7.9x-10.3x11.6x14.0x-15.0x13.9x16.7x-
EV / EBITDA51.7x-71.5x84.5x80.4x-84.3x79.5x108.2x-
Growth
Revenue growth (YoY)1.6%-3.1%3.8%9.8%-7.4%7.6%5.2%-
Revenue CAGR (3y)5.5%-5.9%5.2%6.8%-4.0%3.8%3.8%-
Revenue CAGR (5y)4.5%-3.4%4.3%4.6%-4.8%6.2%6.1%-
Gross profit growth (YoY)-0.3%--6.2%-10.4%6.0%-3.9%14.8%7.7%-
Operating income growth (YoY)-10.7%--18.9%-22.7%31.0%-6.1%26.8%-0.7%-
Net income growth (YoY)-7.6%--15.2%-25.9%10.4%-1.1%32.8%20.1%-
EPS growth (YoY)-0.4%--10.8%-23.2%14.6%-1.4%32.5%18.4%-
EPS CAGR (3y)10.6%-5.7%-6.7%4.8%-3.2%9.8%1.9%-
EPS CAGR (5y)3.8%-1.5%-6.6%7.5%-7.0%8.6%9.4%-
FCF growth (YoY)265.3%----73.1%---66.5%-
FCF CAGR (5y)-4.4%----22.5%---3.9%-
Book value growth (YoY)-28.2%-12.5%-12.9%-0.7%-0.1%1.0%21.2%26.8%34.5%38.7%

Peer comparison

Same SIC group: Services-Home Health Care Services

CompanyRevenue (last FY)Net marginROE
EHAB$1.06B-0.4%-0.9%
ADUS$1.42B6.7%8.8%
OPCH$5.65B3.7%15.7%
AHCO$3.24B-2.2%-4.7%
AVAH$2.43B9.2%115.7%

Comparing CHEMED CORP against the 5 most active filers in the same SIC group.

Dividends

$2.40/share trailing 12 months · +20.0% YoY

Ex-datePer share
May 28, 2026$0.6000
Feb 23, 2026$0.6000
Nov 17, 2025$0.6000
Aug 11, 2025$0.6000
May 29, 2025$0.5000
Feb 24, 2025$0.5000
Nov 18, 2024$0.5000
Aug 12, 2024$0.5000
May 30, 2024$0.4000
Feb 23, 2024$0.4000
Nov 10, 2023$0.4000
Aug 11, 2023$0.4000
May 24, 2023$0.3800
Feb 24, 2023$0.3800
Nov 10, 2022$0.3800
Aug 12, 2022$0.3800
May 25, 2022$0.3600
Feb 25, 2022$0.3600
Nov 12, 2021$0.3600
Aug 13, 2021$0.3600
May 26, 2021$0.3400
Feb 26, 2021$0.3400
Nov 13, 2020$0.3400
Aug 14, 2020$0.3400